Asthma and COPD Meds Flashcards
Step 1 therapy for Asthma in Adults
sxs < 2x/month
- Controller:
- TAke ICS whenever SABA is taken
- Reliever:
- SABA
SABA
short acting beta agonist
Step 2 therapy for Asthma in Adults
sxs 2x/month + but less than 4-5days/week
- Controller:
- low dose maintenance ICS
- Reliever:
- PRN SABA
ICS
inhaled corticosteroid
Step 3 Therapy for Asthma in Adults
sxs most days, or waking with asthma once/week +
- Controller:
- low dose maintenance ICS-LABA
- Reliever:
- PRN SABA
LABA
long acting beta 2 agonist
LTRA
leukotriene receptor antagonist
i.e. singulair (montelukast)
Step 4 Therapy for Asthma in Adults
sxs most days, or waking with asthma once/week+, or low lung function
- Controller:
- medium/high dose maintenance ICS-LABA
- Reliever:
- PRN SABA
Step 5 Therapy for Asthma in Adults
- Controller:
- add on LAMA
- refer for phenotypic assessment
- +/- anti-IgE, anit-IL5/5R, anti-IL4R
- consider high dose ICS-LABA
- Reliever:
- PRN SABA
Age for pediatric asthma tx
6-11 years old
Step 1 therapy for Asthma in Peds
sxs <2x/month
- Controller:
- low dose ICS whenever SABA is taken; or daily low dose ICS
- Reliever:
- PRN SABA
Step 2 Therapy for Asthma in Peds
sxs 2x/month+ but less than daily
- Controller:
- daily low dose ICS
- other:
- daily LTRA, or low dose ICS taken whenever SABA taken
- Reliever:
- PRN SABA
Step 3 Therapy for Asthma in Peds
sxs most days, or waking with asthma 1x/week+
- Controller:
- low dose maintenance ICS-LABA or medium dose ICS
- Other:
- low dose ICS + LTRA
- Reliever:
- PRN SABA
Step 4 Therapy for Asthma in Peds
sxs most days or waking with asthma 1x/week + AND low lung function
- Controller:
- medium dose ICS-LABA and refer for expert advice
- other:
- high dose ICS-LABA, or add on tiotropium or add on LTRA
- Reliever:
- PRN SABA
Step 5 Therapy of Asthma for Peds
- Controller:
- Refer for phenotypic assessment + add-on therapy. e.g. anti-IgE
- other:
- add-on anti-IL5, or add on low dose OCS but consider side-effects
- Reliever:
- PRN SABA
SABAs
Short acting beta-2 agonists
- albuterol
- levalbuterol
- metaproterenol
- Terbutaline
Albuterol (Proventil-HFA; Proair-HFA)
SABA: MDI and neb
- dosing: 2puffs Q4-6hours (90mcg/puff)
- stimulates beta-2 receptors = bronchial muscle relaxation
-
SEs: HypoK especially during continuous neb
- beta-2 stimulation causes cellular uptake of K+ = decreased srum K+
- also tachycardia (because not very selective and will stimulate beta-1 receptors)
Levalbuterol (Xopenex-HFA)
SABA: MDI and neb
- steroisomer of albuterol, but higher affinity for beta-2 so less sysstemic sympathetic effects = b/c less binding to beta-1
- SEs: HypoK
Metaproterenol (Alupent)
SABA: PO
-
SEs: palpitations
- tachycardia
- hypoK
- tremor
- HA, nausea, nervousness
Terbutaline
SABA: PO or pareneteral (SQ injection)
- often used for acute attack (0.25mg SubQ)
-
SEs:
- SABA
- tocolytic
- not approved for children <6yo
LABAs
long acting beta-2 agonists
- salmeterol DPI (Serevent Diskus)
- Formoterol DPI (Foradil)
- Arformoterol (Brovana)
- not for kids
- Indacaterol (Arcapta)
- not for kids
- Olodaterol (striverdi Respimat)
- (Some Fish Are Inherently Odorous)
Salmeterol DPI (Serevent Diskus)
LABA
do not use as monotherapy
- partial agonist
Formoterol DPI (Foradil)
LABA
- helpful for nighttime sxs
- full agonist
- onset = to that of albutero but DO NOT USE FOR ACUTE BRONCHOSPASM
- SEs: paradoxical bronchospasm
Arformoterol (Brovana)
LABA: neb
- used for COPD only!!
- 2x more potent than formoterol
-
SEs:
- paradoxical bronchospasm
- palpitation/tachy/tremor
- lightheadedness/nervousness/HA/nausea
- NOT APPROVED FOR CHILDREN
Indacaterol (Arcapta)
LABA: DPI
- for COPD
-
SEs:
- paradoxical bronchospasms
- palpitations/tachy/tremor
- nervousness/lightheadedness/HA/nausea
- NOT APPROVED IN CHILDREN
Olodaterol (Striverdi Respimat)
LABA: inhaler
- Long half life!! t1/2 = 45hours
-
2C9 substrate = increased side SEs
- plus Same SEs as other LABAs
Inhaled Corticosteroids (ICS)
MOA: inhibit inflammatory cells (mast cell, eosinophils, neutrophils) and cytokines (histamine, leukotriens)
**Flat dose response curve = double the dose adds limited additional effect **
BID Dosing is better (need more in smokers)
- Beclomethasone HFA (QVAR)
- Budesonide DPI (Pulmicort)
- Ciclesonide (Alvesco)
- Fluticasone HFA (Flovent)
- Fluticasone DPI (Flovent Diskus)
- Flunisolide (Aerobid)
- Mometasone DPI (Asmanex)
-
SEs:
- oral candidiasis
- cough
- Dysphonia
- Adrenal Suppression (at high dose)
Omalizumab (Xolair)
monoclono- anti-IgE antibody
- stops release of inflammatory mediatorys
- used for moderate to severe asthma
- significantly reduces ICS use
- SQ injection
-
SEs:
- injection site rxn, bruising, redness, pain, stinging, itching etc
- anaphylaxis (rare)
- monitor 2 hours after injection for 3 months then 30 min thereafter
Combined ICS/LABA
- Fluticasone/Salmeterol (Advair) DPI
- Fluticasone/Vilanterol (Breo Ellipta)
- +3A4 inhibitors (both advair and breo) = increased LABAs = QT prolongation
- Budesonide/Formoterol HFA (Symbicort)
- Mometasone/Formoterol (Dulera)
-
SEs: Thrush
- dysphonia
- pharyngitis
- HA
- nausea
- tremor
GOLD 1-4
for COPD
- Gold 1: FEV1 >80%
- mild
- Gold 2: FEV1 50-79%
- moderate
- Gold 3: FEV1 30-49%
- severe
- Gold 4: FEV1 <30%
- very severe
ABCD categorization of COPD

Stage A COPD Tx
- First Line:
- SABA prn or SAMA prn (bronchodilators)
- Second Line:
- LAMA or LABA or SABA + SAMA
Stage B COPD Tx
- First line:
- LAMA or LABA (long acting bronchodilators)
- Second Line:
- LAMA + LABA
Stage C COPD Tx
- First line:
- ICS + LABA or LAMA
- Second Line:
- LAMA + LABA
- LAMA + PDE4i
- LABA + PDE4i
- LAMA + LABA
Stage D COPD Tx
- First Line:
- ICS + LABA and/or LAMA
- Second Line:
- ICS + LABA and LAMA
- ICS + LABA and PDE4i
- LAMA + LABA
- LAMA + PDE4i
Phosphodiesterase (PDE)-4 inhibitors
inhibit breakdown of cAMP = reduction of inflammation
Roflumilast (Dalirespt)
- for prevention of COPD
-
SEs:
- diarrhea, decreased appetite, weight loss, abdominal pain
- headache, insomnia
- anxiety and depression
- DDI: CYP 1A2 and 3A4
- inducers: butalbital, phenytoin, rifampin, carbamazepine (avoid use)
- inhibitors: amiodarone, clarithromycin, cimetidine, ketoconazole (use with caution)
Most common bacterial organisms associated with mild exacerbation of COPD and More Severe COPD
- Mild:
- strep pneumo, H.flu, Moraxella
- Severe:
- E.coli, Klebsiella, enterobacter, pseudomonas
Pseudomonas risk factors
- 4 or more courses of abx over the past year
- recent hospitalization (2+ days in past 90)
- isolation of pseudomonas during a previous hospital visit
- severe underlying COPD
- FEV1<50
Mepolizumab (Nucala)
monoclondal antibody that targets IL-5
- IL-5 stimulates matural and release of eosinophils in bone more = inflammation
- Indication: maintenance tx of severe asthma age >/=12 yo
-
SEs:
- anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash
- herpes zoster has occurred: IZ if appropriate prior to starting therapy
Reslizumab (Cinqair)
monoclonal antibody against IL-5
- indications: add on maintenance tx with severe asthma for >/= 18 yo and an eosinophilic phenotype
- IV infusion only
-
SEs:
- anaphylaxis, malignancy
- CPK electation = adverse muscle related rxns
- oropharyngeal pain
Methylxanthines
theophylline
inhibit phosphodiesterase = bronchodilation
- less effective than ICS
- narrow therapeutic index 5-15mcg/mL
- metabolized by CYP 1A2 and 3A4
- DDI: inducers: carbamazeine, phenytin, rifampin, ST. John Wort
- inhibitors: clarithromycin, telithromycin, ketoconazole, itraconazole, voriconazoe, grape fruit juice
- SEs:cardiac arrhythmias, seizures
- DDI: inducers: carbamazeine, phenytin, rifampin, ST. John Wort
LAMAs
long acting muscarinic antagonists
- Tiotroprium
- alcidinium
- glycopyrrolate
- Umeclidinium
SABA + Anticholinergic
- Albuterol/Ipratroprium (Combivent Respimat)
- Duoneb
-
SEs: paradoxical bronchospasm
- palpitations/tremor/tachy
- CONTRAINDICATION: soy or peanut allergy
- NOT for Children
Leukotriene Inhibitors
only for asthma (LTRA)
- montelukast (Singulair)
- Zileuton (Zyflo)
- SEs: hepatotoxicity
- DDIs:
- inducers: rifampin, carbamazepine, St. John’s wort
- inhibitors: fluconazole, amiodarone, fluvoxamine, metronidazole, voriconazole
Omalizumab (Xolair)
immunomodulator (anti-IgE antibody)
- inhibits biding of IgE onto mast cells and basophils = stops release of inflammatory mediators
mainly used in COPD, but also for moderate-severe asthma
- SQ injects Q2-4 weeks in clinic, must be observed 2 hours after injection x 3months, then 30 min thereafter.
- significantly reduces use of ICS
Abx for COPD exacerbation outpt (⅓ cardinal sxs)
Mild, no abx needed
cardinal sxs: increased dyspnea, sputum volume, or purulence
Abx for COPD exacerbation outpt (⅔) no risk factors
macrolide
2nd and 3rd gen ceph
doxy
Septra (TMP/Sulfamethoxazole)
Abx for COPD exacerbation outpt (⅔ cardinal signs) with risk factors
respiratory FQs (moxi/levo/gemi)
Amoxicillin/Clavulanate (Augmentin)
Abx for COPD exacerbations in hospital (⅔ of cardinal) with risk factors for pseudomonas
FQ (levo PO or IV)
Cephalosporins (Cefepime IV or Ceftazidime IV)
Zosyn IV (piperacillin + tazobactam)
Abx for COPD exacerbations in hospital (⅔ cardinal) with no pseudomonas risk
FQ (levo or Moxi)
Cephalosporins (ceftriaxone or cefotaxime)
Complicated COPD
FEV1<50%
age >65
>/= 3 exacerbations/year
cardiac disease